

Investment Highlights

- One major platform with multiple high-value applications
- Experts in stable carbohydrate chemistry
- Quick-to-market products
- Non-dilutive funding for major cosmetic program
- Scalable, lean business model
- Opportunity to improve existing products
- Respected, influential scientists

Recent News

- Major grant received to fund depigmenting agent to commercial-ready stage
- Cancer vaccine antigen formulated
- Dr. Stuart Maddin, world-renowned dermatologist, appointed to SAB
- SBM Acquires France-based TFChem
- Positive preclinical results for diabetes compound, an SGLT inhibitor


Company Overview

Our Goal: Minimize Risk, Cost and Time-to-Market

Sirona Biochem Corp. is a biotechnology company with expertise in carbohydrate-based chemistry. We are applying a proprietary chemistry technology towards the development of three major programs - therapeutics, cosmeceuticals and biological ingredients. Using a fluorine chemistry technique, Sirona Biochem aims to improve the pharmaceutical properties of carbohydrate-based molecules.

Platform Technology Overview

A Solution to Unstable Carbohydrates



Stock Information

TSX-V: SBM
OTC: SRBCF
Frankfurt: ZSB

As of Nov 2011

- Market Cap: \$9.8M
- Outstanding Shares: 65M
- Fully Diluted: 83.43M



Quick Facts

- Employees
 - Vancouver - 6
 - France - 8
- Locations
 - Vancouver - Corporate
 - France - Laboratory
- Company Credentials
 - 1 MD
 - 6 PhD
- Founded in 2006 by Dr. Howard Verrico
- TFChem, subsidiary of Sirona Biochem

Our Programs at a Glance

One Major Expertise, Multiple Opportunities

Therapeutics

Diabetes

- SGLT Inhibitor

Cancer Vaccines

- Antigen - key component

Future Projects

- Pain
- Inflammation

Cosmeceuticals

Depigmenting Agent

- Skin lightener

Anti-aging Agent

- Protects skin fibroblasts from UV

Biologics

DNA Inducer

- Recombinant Protein Production
 - Insulin
 - Human growth hormone
 - Interferon (anti-viral)
 - Interleukin (immune)

Cell Preservation

- Stem/Islet/blood cells
- Organ Transplants


Quick to Market

Contact Information

955 - 789 West Pender Street
Vancouver, BC, V6C 1H2
604.641.4466
1.888.SIRONA1 (7476621)
info@sironabiochem.com

Our Proprietary Technology

The 'Superglue' of Carbohydrate Chemistry



Carbohydrate-based molecules have immense potential as therapeutics, cosmetic ingredients and biological ingredients for manufacturing. However, carbohydrate-based molecules are very complex and tend to be unstable. Using our proprietary fluorination process, we have found a way to stabilize these molecules giving us an opportunity to fully exploit their potential. We feel our expertise in carbohydrate-based chemistry can be applied to existing unstable drugs, shelved compounds, patent-expiring products and other biological uses.

Pipeline

Targeting High-value, Unmet Markets

Programs	Target compound identified	Target compound produced	Validation
Therapeutics SGLT Inhibitor Cancer Antigen	██████████	██████████	██████████
Cosmeceuticals Skin Lightener Anti-aging	██████████	██████████	██████████
Biological Ingredients Inducers Adjuvants	██████████	██████████	██████████

Market Opportunity

Skin Lighteners

Source: Global Industry Analysts

- Global market estimated to be **US\$7.5B** in 2009.
- Sales projected to exceed **US\$10B** by 2015
- About 15% of the global population invests in skin lightening products.
- One third of the Chinese population uses skin lightening products on a daily or weekly basis.
- 62% of women in India use skin lightening products on a regular basis
- In Japan alone, an estimated US\$5.9B was spent on skin lighteners
- Fastest growing market is Asia-Pacific growing at a compounded annual growth rate (CAGR) of 8.4%

Diabetes

- Diabetes global market estimated at **\$25B**
- 220 million+ people worldwide have diabetes
- An estimated 1.1 million people died from diabetes (2005)
- Diabetes deaths are projected to double between 2005 and 2030.
- BMS/AstraZeneca's Dapagliflozin, SGLT inhibitor pending FDA approval
- Most recent diabetes drug launch, Januvia, reached \$2.4B in 2010 within four years, estimated to be \$4.5B in 2013
- Recent diabetes pharmaceutical deals
 - Forest Laboratories licenses TransTech's Phase 1 Glucokinase Activators for \$50M upfront, \$1.1B milestones
 - Boehringer licenses Neurocrine's GPR119 receptors (discovery phase) for \$10M upfront, \$225M in milestones

Management Team

Seasoned Team in Science & Business

Howard Verrico, MD

Founder, President & CEO
 • MD, Emergency Physician
 • CEO/Director, Ecoprogress

Christopher Hopton, CGA

Chief Financial Officer
 • Previously with Central Resources Corp., Canadian Airlines, 360 Networks

Geraldine Deliencourt-Godefroy, PhD

Chief Scientific Officer
 • Award-winning chemistry
 • Founder of TFChem

Bertrand Plouvier, PhD, PMP

VP, Product Development
 • Head of Chemistry, Cardiome
 • Discovery & development of Vernakalant

Scientific Advisory Board

Top Scientists in their Field

Stuart Maddin, MD, FRCPC

• Dermatology Expert
 • Editor-in-Chief, Skin Therapy Letter

Mario Pinto, PhD

• VP, Research, SFU
 • World leader - carbohydrate mimicry research

Denis Richard, PhD

• Diabetes/Obesity expert
 • Professor, Laval University

Michael Walker, PhD

• CEO of Verona Pharma
 • Founder of Rhythm Search Developments, now Cardiome

Bruce Verchere, PhD

• Head of Diabetes Program, BC Research Institute for Children's & Women's Health
 • Professor, UBC

Jacques Warcoin

• CEO of French law firm, Cabinet Regimbeau
 • Global expert in living organisms patentability

TFChem

- Pierre Vogel, PhD
- Eric Leclerc, PhD
- Bernard Langlois, PhD

Sirona Biochem cautions you that statements included in this profile that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements.

TSX-V: SBM